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Increased DNA methylation variability in type 1
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The incidence of type 1 diabetes (T1D) has substantially increased over the past decade,
suggesting a role for non-genetic factors such as epigenetic mechanisms in disease development.
Here we present an epigenome-wide association study across 406,365 CpGs in 52 monozygotic
twin pairs discordant for T1D in three immune effector cell types. We observe a substantial
enrichment of differentially variable CpG positions (DVPs) in T1D twins when compared with their
healthy co-twins and when compared with healthy, unrelated individuals. These T1D-associated
DVPs are found to be temporally stable and enriched at gene regulatory elements. Integration with
cell type-speciﬁc gene regulatory circuits highlight pathways involved in immune cell metabolism
and the cell cycle, including mTOR signalling. Evidence from cord blood of newborns who progress
to overt T1D suggests that the DVPs likely emerge after birth. Our ﬁndings, based on 772
methylomes, implicate epigenetic changes that could contribute to disease pathogenesis in T1D.
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T
ype 1 diabetes (T1D) is a common, organ-speciﬁc
autoimmune disease that results from the progressive loss
of insulin-producing b-cells in the pancreas. Genetic
predisposition and environmental factors contribute to the
disease onset1. The incidence of T1D has dramatically increased
in recent years (3–4% per annum), with the most rapid upsurge
seen in children younger than ﬁve years of age2. The increasing
rate of T1D, along with disease discordance in monozygotic (MZ)
twins, suggest that non-genetic factors play a major role3,4.
Such factors, including viral and bacterial infections, diet,
and potentially epigenetic and stochastic events, may affect
disease predisposition either in utero or in early childhood when
predictive autoantibodies emerge3. However, conclusive evidence
about causal environmental factors in T1D pathogenesis has not
been obtained to date.
Epigenetic modiﬁcations, including DNA methylation, are cell
type-speciﬁc and induce stable changes in gene expression that
are heritable during cell division. DNA methylation occurs at
cytosine residues mainly in the context of CpG dinucleotides, and
is generally associated with transcriptional silencing5. It can
contribute to disease development and progression through its
inﬂuence on gene expression, and function as mediator in
response to environmental stimuli6. In systematic epigenome-
wide association studies (EWASs), DNA methylation levels are
typically measured at hundreds of thousands of CpG sites across
individuals in a case-control cross-sectional cohort. CpG sites are
then associated with disease status, and differences in DNA
methylation levels between cases and controls are recorded7,8.
However, it has to be noted that the meaningful interpretation
of EWAS ﬁndings is impeded by several confounding
factors, in particular cellular heterogeneity in accessible
sample material (for example, peripheral blood) and genetic
heterogeneity between individuals7,9.
Disease-associated CpG sites can be identiﬁed using different
analytical approaches (Fig. 1). Most EWASs have sought to
quantify differences in mean DNA methylation at CpG sites
between cases and controls, that is, differentially methylated
CpG positions (DMPs). In recent years, DMPs have been shown
to associate with a multitude of complex traits and diseases,
including blood pressure10, triglyceride levels11, pain sensitivity12,
schizophrenia13, rheumatoid arthritis14 and T1D (refs 15,16).
However, the difference in mean DNA methylation at these CpGs
is often small (o5%), raising challenges to their biological
interpretation.
In parallel, the potential importance of increased DNA
methylation variability has been noted in cancerous tissue17–22.
Differentially variable CpG positions (DVPs) are heterogeneous
outlier events that occur mainly, if not exclusively, in disease cases
(Fig. 1). DVPs usually involve larger shifts in DNA methylation
(410%), albeit in a smaller number of cases. For example, DVPs
have recently been identiﬁed in precursor cervical cancer lesions
that are predictive of progression to neoplasia when compared
with matched control tissue21. The contribution of such DNA
methylation outliers in non-cancerous tissues has not yet
been evaluated. Further, the distinct functional characteristics of
DVPs compared with those of DMPs have not been fully
appreciated.
In this study, we determine differential DNA methylation in 52
MZ twin pairs discordant for T1D. In these twin pairs, we
perform an EWAS in immune cells known to act as key drivers in
the disease process, namely CD4þ T cells, CD19þ B cells and
CD14þCD16 monocytes, using Illumina Inﬁnium Human-
Methylation450 BeadChips (‘450K arrays’). Importantly, our
experimental design reduces the impact of all major confounding
factors in EWASs, due to the proﬁling of puriﬁed, primary cells
derived from MZ twins, who share virtually all somatic variation
and early-life environmental exposure23. With the exception of
one DMP in T cells, we do not identify signiﬁcant T1D-associated
DMPs in any of the investigated immune cell types. However, we
ﬁnd a strong enrichment of DVPs in T1D twins relative to their
healthy co-twins. We also observe a cell type-speciﬁc enrichment
when compared with healthy, unrelated individuals. These
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Figure 1 | Overview of the study design and analytical approach. We performed an EWAS in 52 MZ twin pairs discordant for T1D in three immune
effector cell types: CD4þ T cells, CD19þ B cells and CD14þCD16 monocytes. We used two different approaches to determine differential DNA
methylation associated with T1D status in disease-discordant twin pairs. First, we identiﬁed DMPs between T1D and healthy co-twins, which correspond to
differences in mean DNA methylation levels. Second, we determined DVPs, which reﬂect heterogeneous ‘epigenetic outliers’ in T1D twins compared with
their healthy co-twins. To assess the biological signiﬁcance of our ﬁndings, we analysed three additional, genome-wide DNA methylation data sets in
CD14þ monocytes and CD4þ T cells from 12 T1D-discordant MZ twin pairs; CD14þ and CD4þ cells from 201 and 139 unrelated, healthy individuals;
and cord blood from 98 newborns of whom 50 had progressed to overt T1D during childhood. Finally, we characterized T1D-associated DVPs using cell
type-speciﬁc gene regulatory circuits. Credits: The immune response, Big Picture (http://bigpictureeducation.com/).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13555
2 NATURE COMMUNICATIONS | 7:13555 | DOI: 10.1038/ncomms13555 | www.nature.com/naturecommunications
T1D-associated DVPs are temporally stable; not under genetic
control; enriched at gene regulatory elements; and located at
genes involved in immune cell metabolism and the cell cycle.
Results
DNA methylation proﬁles of immune effector cell types. In 52
T1D-discordant MZ twin pairs, we isolated three immune
effector cell types that play a pivotal role in T1D pathobiology:
CD4þ T cells, CD19þ B cells and CD14þCD16 monocytes1.
Cells were isolated and puriﬁed from collected peripheral blood
mononuclear cells using magnetic activated cell sorting (MACS).
Cell purity of each preparation was evaluated using ﬂuorescence-
activated cell sorting (FACS) analysis (Supplementary Fig. 1).
For the discovery stage, we generated a total of 302
genome-wide DNA methylation proﬁles on the 450K array
platform (Fig. 1). The array platform allows the assessment of
DNA methylation status at 4485,000 CpG sites at single-
nucleotide resolution, and covers 99% of RefSeq genes with an
average of 17 CpG sites per gene region and 96% of CpG
islands24. Array data preprocessing and quality control were
performed using established analytical tools (see the ‘Methods’
section), leaving 406,365 CpG sites for subsequent statistical
analysis (Supplementary Fig. 2a).
Multidimensional scaling and hierarchical clustering revealed
that most of the variation in the data was captured by variation
between twin pairs (for example, genetic effects) and cell types
(Supplementary Figs 2b and 3). In addition, we performed
singular value decomposition to determine principal components
of variation in DNA methylation proﬁles. In our analysis,
no principal component was found to correlate with T1D status
(Supplementary Fig. 2c).
Identiﬁcation of T1D-associated DMPs. We ﬁrst measured
differences in mean DNA methylation levels between T1D twins
and their healthy co-twins in each cell type using a pair-wise
analysis. We identiﬁed a single DMP at genome-wide
signiﬁcance, cg01674036 in T cells (P¼ 2.2 10 9, false
discovery rate (FDR)-corrected P¼ 9.1 10 4, paired t test;
Fig. 2a). This DMP demonstrated a mean DNA methylation
difference of 2.3% between T1D and healthy co-twins, and
mapped to an intergenic region 24.3 kb downstream of the DDIT4
gene (also known as REDD1) encoding DNA-damage-inducible
transcript 4 (Fig. 2b). Notably, we did not detect any additional
DMPs at an FDR of o0.05 in any of the three cell types.
The DMP cg01674036 co-located with an active gene
regulatory region in T cells (Fig. 2c). Chromatin interaction data
obtained from a lymphoblastoid cell line provided experimental
evidence that this region binds to the promoter region of DDIT4.
DDIT4 functions as an inhibitor of the mammalian target of
rapamycin (mTOR) complex 1; activation of mTOR complex 1 is
controlled by anabolic hormones including insulin25.
The 450K array platform has a ﬁxed set of CpG sites, covering
o2% of all annotated CpGs. While this platform is scalable to
large sample sizes, the complementary application of sequencing-
based approaches is required to comprehensively capture disease-
associated DNA methylation loci on a genome-wide level11,12. To
this end, we further measured DNA methylation levels in CD4þ
T cells using whole-genome bisulﬁte sequencing (WGBS-seq) in
four MZ twin pairs, who were originally proﬁled on the 450K
array. In total, we obtained 4500 million reads per sample
resulting in a mean coverage of between 12.6 and 15.1 reads per
CpG site. This allowed us to investigate over 8.7 million CpGs
with a minimum coverage of 10 reads across all eight samples
(Supplementary Table 1). This analysis was sufﬁciently powered
to detect differentially methylated regions (DMRs) that consist of
at least ﬁve CpGs and exhibit a mean DNA methylation
difference of 430% at an FDR of o0.05. We did not identify
such DMRs to be associated with T1D, irrespective of FDR values.
In conclusion, with the exception of the DMP cg01674036, we
did not identify mean DNA methylation differences between T1D
twins and their healthy co-twins in any of the three immune cell
types using the 450K array platform (Fig. 3a). At genomic loci not
covered by the array, results based on WGBS-seq data indicate
that mean DNA methylation differences of large effect size are
unlikely to exist.
Identiﬁcation of T1D-associated DVPs. Next, we explored
whether DNA methylation variability between T1D-discordant
MZ twins can shed light on the phenotypic discordance. A recent
comparative study26 demonstrated that current algorithms for
DVP detection can substantially differ in terms of their sensitivity
and type-1 error rate (see the ‘Methods’ section). Established
algorithms typically assume frequent alterations in the disease
phenotype, and thus lack the sensitivity to detect outlier events26.
Instead, the novel algorithm iEVORA22, which is based on a
regularized version of Bartlett’s test, improves the sensitivity to
detect DVPs (see the ‘Methods’ section).
Using iEVORA, we identiﬁed 10,548 DVPs in B cells, 4,314 in
T cells and 6,508 in monocytes at a stringent FDR of o0.001
(Fig. 3b). Strikingly, in each cell type we found strong enrichment
of DVPs that are hypervariable in T1D twins compared with their
healthy co-twins (Po1 10 100, binomial test; Fig. 3c). These
T1D-associated DVPs represent ‘epigenetic outliers’ that often
occur in individual twin pairs and cell types (Fig. 4a and
Supplementary Fig. 4). At DVPs, the DNA methylation
differences between the T1D twin and its healthy co-twin were
found to be comparatively large in many cases (Supplementary
Fig. 4).
We next assessed a range of potential confounding factors
that could lead to increased variability in DNA methylation
levels, including cellular heterogeneity and differences in cell
puriﬁcation efﬁciency (as quantiﬁed by FACS), age of twins at
both disease diagnosis and sample collection, medication use
(statins and thyroxine), as well as presence of other autoimmune
diseases (thyroiditis, as characterized by thyroid peroxidase
autoantibodies). We calculated the fraction of DVPs in T1D
twins exhibiting a signiﬁcant deviation from the healthy
co-twins, and then correlated this fraction with different
potential confounding variables. For all tested variables, these
correlations were not statistically signiﬁcant (P40.05;
Supplementary Fig. 5).
DNA methylation levels can associate with genetic variants in
cis, leading to an increase in interindividual DNA methylation
variability. Although post-zygotic somatic mutations may occur
and give rise to mosaicism in identical twins (with a controlled
genetic background)23, due to the heterogeneous nature of DVPs,
we anticipated a modest (if any) genotypic effect on DNA
methylation levels at DVPs. To ﬁnd a deﬁnitive answer, we
genotyped all 52 twin pairs on Illumina HumanOmni2.5–8
BeadChips, and mapped methylation quantitative trait loci
(meQTLs) using a linear-additive modelling approach (see the
‘Methods’ section). For this analysis, only single-nucleotide
polymorphism (SNPs) with a minor allele frequency of 45%
and located o50 kb up- and downstream of each CpG site were
considered. We found that T1D-associated DVPs (FDRo0.001)
were depleted at meQTLs compared with random sets of CpG
sites in all three cell types (permutation Po1 10 4).
In summary, in all three immune cell types we discovered
statistically signiﬁcant DVPs that correlate with T1D status.
We provided evidence that these CpG sites are unlikely to be a
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consequence of confounding factors, including cellular hetero-
geneity, and that they act independently of genetic variation.
Temporal stability of T1D-associated DVPs. Following the
discovery of DVPs on 450K arrays, we reassessed the
T1D-associated DNA methylation hypervariability phenotype in
twins after ﬁve years, using a second assay platform. We retrieved
genome-wide DNA methylation proﬁles of CD14þ monocytes
and CD4þ T cells from 12 T1D-discordant MZ twin pairs gen-
erated on Illumina Inﬁnium HumanMethylation27 BeadChips
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Figure 2 | Assessment of the functional signiﬁcance of the T1D-associated DMP cg01674036. (a) QQ plot for the identiﬁcation of
differentially methylated CpG positions (DMPs) between T1D-discordant MZ twin pairs in different immune effector cell types. Only the DMP cg01674036
reached genome-wide signiﬁcance in T cells, with P¼ 2.2 109 (FDR-corrected P¼ 9.1 104) and a mean DNA methylation difference of 2.3%. (b)
Regional plot of the locus harbouring the T-cell-speciﬁc DMP cg01674036. The statistically signiﬁcant DMP is indicated with a black arrow. Data points
represent the DNA methylation b-values (y axis) at the indicated CpGs (x axis) in one individual. For each CpG site, we calculated the mean DNA
methylation value (indicated with a larger data point). Every CpG site is annotated with regards to epigenomic feature and gene element using the 450K
array annotation manifest. (c) Annotation of the genomic locus using epigenomic reference data sets. The genomic locus on chromosome 10q22.1
(position¼ 74,028,000–74,100,000; genome build¼ hg19) harbouring the DMP cg01674036 (chr10:74,058,002) is shown using the WashU Epigenome
Browser v40.0.0 (http://epigenomegateway.wustl.edu/browser/). The T1D-associated DMP is located at a CpG island (indicated with a red arrow).
A total of 16 epigenomic reference tracks provided by the Roadmap Epigenomics project are displayed. Speciﬁcally, we show both the primary and imputed
chromatin state maps in eight distinct primary T cell populations. The highlighted CpG island overlaps with an active transcription start site (red)
or enhancer (orange/yellow) in all available T cell populations. In addition, H3K4me3 ChIA-PET data in the lymphoblastoid cell line GM12878 revealed a
long-range chromatin interaction between the active regulatory element and the gene promoter region of DDIT4. CGI, CpG island; ChIA-PET, chromatin
interaction analysis by paired-end tag sequencing; IGR, intergenic region.
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(‘27K arrays’)15. These twins belonged to the same twin registry
used for the discovery cohort of this study, but provided new
DNA samples for reassessment after ﬁve years.
We conﬁrmed directionality of the T1D-associated DVPs
(FDRo0.001), indicating robust technical detection across assay
platforms in both CD14þ cells (P¼ 7.7 10 5, one-tailed
Fisher’s exact test; Fig. 3d) and CD4þ cells (P¼ 7.8 10 3;
Fig. 3d). Consistently, the attained positive predictive values were
higher in the direct cell type comparison (Fig. 3e).
Taken together, we showed that DNA methylation levels at
T1D-associated DVPs are temporally stable over at least ﬁve years
in patients with established diabetes, and can be observed across
two assay platforms.
Evaluation of T1D-associated DVPs in unrelated individuals.
We further assessed T1D-associated DVPs using independent
genome-wide DNA methylation proﬁles retrieved from the
BLUEPRINT Consortium. Speciﬁcally, we reasoned that DVPs
hypervariable in T1D ought to be hypervariable when compared
with an external set of healthy controls. We obtained 450K array
data sets of CD14þ and CD4þ cells derived from 201 and 139
unrelated, healthy individuals, respectively. These individuals
were drawn from a population of blood donors, and thus are
unlikely to have strong genetic susceptibility to T1D.
DVPs that were found to be hypervariable in T1D twins
compared with their healthy co-twins, were also hypervariable
when compared with unrelated individuals with limited genetic
susceptibility markers (Supplementary Fig. 6). As demonstrated
before, DVPs showed cell type speciﬁcity (P¼ 1.3 10 60 and
P¼ 4.5 10 107, for monocytes and T cells, respectively).
In conclusion, our analysis provided further evidence that the
identiﬁed DVPs represent relevant, cell type-speciﬁc markers
for T1D.
Assessment of T1D-associated DVPs in cord blood. To explore
whether the identiﬁed DVPs emerged before the onset of T1D, we
generated genome-wide DNA methylation proﬁles of umbilical
cord blood obtained from newborns. These newborns were part
of the DiPiS cohort, a population-based prospective study of T1D
in children27. We selected samples from 98 newborns of whom 50
had progressed to overt T1D during childhood, while 48 did not.
We hypothesized that if the T1D-associated DVPs (that are
independent of genetic risk factors) were already observed in cord
blood before disease onset, they could potentially contribute to
T1D pathogenesis or be an early indicator of disease.
We correlated DNA methylation levels at T1D-associated
DVPs identiﬁed in puriﬁed immune cell types with those in cord
blood tissue. This assessment did not reach statistical signiﬁcance
(P40.05, one-tailed Fisher’s exact test).
Based on these ﬁndings, we conclude that the discovered DVPs
occur post-birth and are likely associated with the pathogenesis
of T1D either before or after the clinical diagnosis. Nonetheless,
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Figure 3 | DNA methylation variation in identical twin pairs discordant for T1D. (a) Histogram of P-values for the identiﬁcation of differentially
methylated CpG positions (DMPs) between T1D-discordant MZ twin pairs in different immune effector cell types. DMPs were determined using a paired
t test. (b) Histogram of P-values for the identiﬁcation of T1D-associated differentially variable CpG positions (DVPs). DVPs were determined at an FDR of
o0.001 using the algorithm iEVORA. (c) Bar plots showing the enrichment of DVPs in T1D twins compared with their healthy co-twins. While this
hypervariability phenotype was found in all cell types (Po1 10 100, binomial test), it was particularly pronounced in B cells. (d) Bar plots showing
the odds ratios of the assessment of temporal stability of T1D-associated DVPs in an external data set of CD14þ and CD4þ cells derived from
12 disease-discordant MZ twin pairs generated on 27K arrays. Importantly, the identiﬁed DVPs in CD14þ and CD4þ cells replicated in a cell type-speciﬁc
context. Stars denote statistical signiﬁcance assessed using a one-tailed Fisher’s exact test: *Po1 10 2 and **Po1 104. (e) Positive predictive values
for the analyses shown in d. B, CD19þ B cells; M, CD14þCD16 monocytes; T, CD4þ T cells.
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Figure 4 | Functional annotation of T1D-associated DVPs. (a) Venn diagram showing the overlap of T1D-associated DVPs (FDRo0.001) across cell
types. Although many of the identiﬁed DVPs were found to be cell type-speciﬁc, B cells and monocytes showed a substantial proportion of overlap.
(b,c) Enrichment of T1D-associated DVPs at different epigenomic features and gene elements. Here, only DVPs at which the DNA methylation level was
increased (hypermethylated; Db40) in T1D twins compared with their healthy co-twins are shown. The enrichment is shown in relation to all 450K array
probes that passed quality control. (d,e) The same analyses as shown in b and c, but for DVPs at which the DNA methylation level was reduced
(hypomethylated; Dbo0) in T1D twins. (f) Integration of T1D-associated DVPs with gene regulatory circuits in CD19þ B cells. The network was
constructed using the corresponding genes of all T1D-associated hypomethylated DVPs that map to gene promoters and hypermethylated DVPs at gene
bodies identiﬁed in B cells. The resulting network consisted of 297 genes connected via 906 regulatory edges. Three network modules were identiﬁed and
are highlighted in different colours: Module 1 (n¼ 61 genes) is shown in purple, module 2 (n¼ 69) in green and module 3 (n¼ 167) in orange. These
modules were further characterized using functional enrichment analysis (Supplementary Table 2 and Supplementary Table 3). IGR, intergenic region;
N, north, that is, upstream; S, south, that is, downstream; TSS200/1500, 200/1500bp upstream of a transcription start site; UTR, untranslated region.
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it should be noted that cord blood, similar to peripheral whole
blood, is a substantially heterogeneous tissue that hampers the
precise measurement of DNA methylation levels. Our study is by
far the most powered in this area, but future studies with
increased statistical power will be needed to corroborate our
conclusions.
Functional signiﬁcance of T1D-associated DVPs. Next, we
investigated whether T1D-associated DVPs exhibit a certain level
of functional organization and whether the nearby genes cluster
in biological pathways. First, we performed enrichment analyses
with regards to gene elements and epigenomic features as deﬁned
in the 450K array annotation manifest. We distinguished between
T1D-associated DVPs (FDR o0.001) at which the DNA
methylation level is either increased (hypermethylated) or
decreased (hypomethylated) in T1D twins compared with their
healthy co-twins. This discrimination is important, because the
effect of DNA methylation on the regulation of gene expression
is distinct at different gene elements5,28. Across the three
immune cell types, we found an enrichment of T1D-associated
hypermethylated DVPs at CpG islands (P¼ 1.5 10 265,
hypergeometric test; Fig. 4b) and proximal gene promoters
(P¼ 2.3 10 131; Fig. 4c). In contrast, hypomethylated DVPs
were depleted at CpG islands (Po2.2 10 308; Fig. 4d) and
enriched at gene bodies (P¼ 1.0 10 47; Fig. 4e).
We corroborated these enrichment patterns using cell type-
speciﬁc chromatin state maps. We retrieved reference chromatin
state data based on ﬁve chromatin marks in primary cells from
peripheral blood, provided by the Roadmap Epigenomics
project29 (see the ‘Methods’ section). For all three immune cell
types, we found cell type-speciﬁc enrichment of T1D-associated
hypermethylated DVPs at chromatin states marking active
transcription start sites proximal to gene promoters
(Po2.2 10 308 in B cells, P¼ 4.2 10 38 in T cells,
and P¼ 5.2 10 262 in monocytes, hypergeometric tests;
Supplementary Fig. 7a). We also observed depletion at states
marking enhancers (P¼ 6.2 10 269 in B cells, P¼ 3.4 10 22
in T cells, and P¼ 1.3 10 258 in monocytes; Supplementary
Fig. 7a). Hypomethylated DVPs showed inverted enrichment
patterns (Supplementary Fig. 7b).
We then tested for enrichment of biological process ontology
terms attributed to genes in proximity to T1D-associated DVPs.
We adjusted for the differing number of CpGs per gene present
on the 450K array to reduce bias in the gene set analysis30. Across
all cell types, the T1D-associated DVPs cumulatively clustered at
genes involved in molecular metabolic processes and the cell
cycle (Supplementary Fig. 8). The enrichment was particularly
pronounced in B cells (Supplementary Fig. 8).
In summary, these ﬁndings showed that T1D-associated DVPs
localize at speciﬁc gene regions and active chromatin states
implicated in the regulation of gene expression, and highlighted
gene pathways related to cell metabolism and the cell cycle.
Integration of T1D-associated DVPs with regulatory circuits.
Finally, using a gene regulatory network approach we further
explored the T1D-associated DVPs in B cells that may lead to
transcriptional regulation of relevant pathways. We obtained
CD19þ B-cell-speciﬁc regulatory circuits31 that consist of
interactions between transcription factors and genes derived
from genome-wide promoter and enhancer activity maps
presented by the FANTOM5 project32,33. We deﬁned two sets
of DVPs that may lead either to transcriptional repression or
activation in B cells, and assigned these to their corresponding
genes (see the ‘Methods’ section). Then, we intersected the
resulting gene lists with the regulatory circuits.
The regulatory network created using ‘gene-repressing’ DVPs
consisted of 1,465 genes and 16,712 regulatory edges. The
corresponding network constructed using ‘gene-activating’ DVPs
consisted of 297 genes connected via 906 edges. While we were
unable to resolve the structure of the gene-repressing network
and could not identify signiﬁcant modules within this network,
the gene-activating network showed three network modules
(Fig. 4f). We further characterized these modules using gene
enrichment analyses (see the ‘Methods’ section), and the results of
all gene set analyses are shown in detail in Supplementary
Table 2.
Module 1 contained 61 genes, including NRF1 encoding
nuclear respiratory factor 1 (Fig. 4f; shown in purple). NRF1 is a
transcription factor that regulates the expression of genes
encoding key enzymes in oxidative metabolism and mitochon-
drial function34. The module showed enrichment in ontology
terms related to glucose-6-phosphate transmembrane transporter
activity. Further analysis revealed overrepresentation of genes
involved in mTOR signalling, a central pathway in the regulation
of cell metabolism, growth and proliferation (Supplementary
Table 3)35. Module 2 contained 69 genes (Fig. 4f; shown in
green), and was enriched for genes connected to interleukin-1
receptor binding and receptor antagonist activity. This pathway is
implicated in T1D-associated altered innate immunity36.
Module 3 contained 167 genes, including the FOXP1 gene hub
(Fig. 4f; shown in orange). FOXP1 encodes forkhead box P1, an
important transcriptional regulator of B cell, T cell and monocyte
differentiation. Recent studies in mice also demonstrated that
Foxp1 is essential for islet a-cell proliferation and function37,
and plays a key role in the regulation of systemic glucose
homeostasis38.
The integration of T1D-associated DVPs with gene regulatory
circuits in CD19þ B cells conﬁrmed our initial ﬁndings
(Supplementary Fig. 8), and further implicated signalling
pathways related to immune cell metabolism. While
alteration in these pathways could be secondary to the systemic
metabolic abnormalities associated with diabetes, we note that
these pathways could also predispose to autoimmune diseases
including T1D.
Discussion
In this study, we investigated whether differential epigenetic
variation can explain discordance of T1D in identical twins. We
measured genome-wide DNA methylation levels in 52 twin pairs
across disease-relevant immune effector cell types. Our unique
study design allowed us to reduce confounding factors that have
impeded many previous EWASs, namely cellular heterogeneity
(by using multiple, sorted, primary cell types) and genetic
heterogeneity, age and early-life environmental effects (by using
disease-discordant MZ twins).
Notably, with the exception of a single T-cell-speciﬁc DMP, we
did not detect convincing differences in mean DNA methylation
associated with T1D in our MZ twin cohort using the 450K array
platform (FDRo0.05; Fig. 2a). The DMP that did reach statistical
signiﬁcance, cg01674036 in CD4þ T cells, is not contained on the
27K array platform and therefore could not be technically
replicated in our data set. Annotation using epigenomic reference
data sets revealed that the DMP maps to an active gene regulatory
region in T cells and interacts with the gene promoter of
DDIT4 (Fig. 2c). The corresponding protein is involved in the
mTOR signalling pathway, which has been implicated in the
gene network analysis of T1D-associated DVPs (Fig. 4f and
Supplementary Table 3).
In addition, we did not ﬁnd DMRs of large effect size
(430%; Z5 CpGs) in four disease-discordant MZ twin pairs
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using WGBS-seq. It is possible that T1D-associated DMPs and
DMRs could be discovered in much larger cohorts or more highly
selected cell populations using either Inﬁnium arrays or bisulﬁte
sequencing39. In particular, the recent availability of the Illumina
Inﬁnium MethylationEPIC BeadChip covering over 850,000 CpG
sites40, of which many are located at enhancer regions identiﬁed
by the ENCODE and FANTOM5 projects, may allow for
discovery of additional T1D-associated loci. However, if they
were present, such loci would most likely be of small effect size.
Indeed, this notion would be consistent with ﬁndings from
genome-wide association studies (GWASs) of T1D and other
complex traits and diseases. In GWASs, many hundreds of trait-
associated genetic variants have been identiﬁed, the vast majority
of which possess small effect sizes41.
In contrast, we identiﬁed a substantial number of CpGs that
are hypervariable in T1D twins compared with their healthy
co-twins. The DNA methylation differences at DVPs were found
to be comparatively large in many cases (Supplementary Fig. 4).
The sensitive yet robust identiﬁcation of DVPs is challenging, and
is characterized by a high type-1 error rate22. Thus, replication of
our ﬁndings in independent sample cohorts in future studies is
paramount.
Here, for the ﬁrst time, we detected and functionally annotated
DVPs in a common disease phenotype other than cancer.
DVPs have been shown to correlate with the early stages
of carcinogenesis. Consistently, our data suggest that
T1D-associated DVPs are associated with T1D after clinical
diagnosis. In this regard, causal inference analysis may be applied
to further characterize and quantify the extent of the relationship
between genetic variants, epigenetic variants and phenotypic
discordance14,42. Future longitudinal studies of pre-diabetic
individuals will establish whether the epigenetic changes
antedate the clinical diagnosis.
Our ﬁndings have important implications for the future
application of the EWAS approach to elucidate human disease
mechanisms. First, the use of puriﬁed, primary cell populations
likely reduced the overall number of association signals typically
detected in case-control EWASs conducted in peripheral blood,
but with the critical advantage of yielding genuine disease-
relevant signals, if present. Second, we propose the complemen-
tary assessment of DNA methylation variability in parallel to
mean DNA methylation for any future EWAS. Analytical tools
are now readily available to identify DVPs for other complex
traits and diseases19,22.
Our results showed that DVPs differ considerably between the
proﬁled cell types (Fig. 4a and Supplementary Fig. 4), suggesting
that the response of each cell type is speciﬁc. The importance of
the three immune effector cell types used in this study in the
development of T1D has been recognized through experimental
evidence1,3. Furthermore, genetic variants associated with T1D
are enriched at enhancer sequences active in T and B cells, as well
as CD34þ stem cells and thymus tissue43. However, it is plausible
that other cell types not assayed here may contain relevant DNA
methylation differences. Alternatively, it may also be possible that
rare sub-populations of the three immune cell types, such as
regulatory T cells (CD25þFOXP3þ cells) or T helper 17 cells
(TH17 cells), harbour epigenetic signals that remain undetected in
the broad population of CD4þ T cells1,44,45. Future EWASs in
subsets of T cells may be conducted to address this possibility.
Of note, a recent report found an increase in DNA
hydroxymethylation levels at gene promoters in CD4þ T cells
in patients with systemic lupus erythematosus, an autoimmune
disease, compared with healthy controls46. DNA hydroxy-
methylation remodelling has also been observed in CD4þ
T cell differentiation47. As our experimental approach did
not allow the discrimination between methylated and
hydroxymethylated cytosine bases, DNA hydroxymethylation
could thus contribute to the observed differential variability,
potentially providing a general mechanism underlying the
pathogenesis of autoimmune diseases.
Studies have reported the co-localization of meQTL at genetic
risk loci of complex traits and common diseases identiﬁed
through GWASs, including schizophrenia13, blood pressure10,
and several cancer types48. Consequently, we overlapped our
T1D-associated DVPs with 59 T1D genetic susceptibility loci
retrieved from T1DBase, a curated web resource (http://www.
t1dbase.org; v4.19). We did not ﬁnd a statistically signiﬁcant
enrichment of DVPs at these loci (P40.05, hypergeometric test).
A speciﬁc enrichment test of T1D-associated DVPs mapping to
the major histocompatibility complex (MHC) locus also did not
achieve statistical signiﬁcance compared with all assessed CpG
sites (Supplementary Fig. 9). The MHC locus is key in conferring
genetic risk of T1D and other autoimmune diseases, as it
harbours many genes encoding cell surface molecules that
orchestrate components of the immune system. This analysis
provided further evidence that T1D-associated genetic and
epigenetic variants appear to act independently.
We have identiﬁed T1D-related DVPs in immune effector cells
that associate with genes involved in cell metabolism and the cell
cycle (Supplementary Fig. 8 and Supplementary Table 2).
Speciﬁcally, by integrating T1D-associated DVPs with gene
regulatory circuits in CD19þ B cells, we pinpointed key
transcriptional regulators such as NRF1 and FOXP1 (Fig. 4f),
and pathways such as mTOR signalling (Supplementary Table 3).
Indeed, the same signalling pathways have been implicated in
differentiation, proliferation and metabolism of both T cells and
monocytes49–52. For example, deletion of Foxp1 in naı¨ve CD8þ
T cells leads to activation of the mTOR signalling cascade53,
indicating a relationship between gene modules 1 and 3 of the
regulatory network we identiﬁed here (Fig. 4f). Therefore, DVPs
could modulate disease activity through the regulation of immune
effector cell gene expression either before or after the induction of
the disease process.
However, it remains possible that other T1D-associated DVPs
result from disease-associated metabolic disturbances. Previous
studies reported DMPs (including cg19693031) at the TXNIP
gene to be inversely correlated with both type 2 diabetes and
sustained hyperglycaemia (for example, haemoglobin A1c
levels)54,55. In our data set of T1D patients, we also found
cg19693031 to be a DVP in monocytes (P¼ 9.1 10 4); this
observation suggests that a proportion of DVPs result from the
diabetes-associated metabolic effect. In either case, it is likely that
the impact of epigenetic changes on T1D-associated immune
effector cells would adversely affect the natural history of the
disease3.
The exact mechanism by which epigenetic instability in T1D is
manifested, its timing in relation to induction of islet auto-
immunity, as well as its impact on disease progression, remains to
be explored. However, these questions can now be addressed
through the study of individuals at high T1D-risk and those
with variable disease severity. In this way, we can achieve our
ultimate aim of identifying diagnostic and prognostic epigenetic
biomarkers that can improve the management of T1D.
Methods
Ethics statement. This study was approved by the Northern and Yorkshire
Research Ethics Committee (REC reference number: 06/MRE03/22) and the NRES
Committee East of England-Hertfordshire (12/EE/0040). All participants gave
informed consent either personally or by parental consent, as appropriate.
Study samples. MZ twin pairs were ascertained by referral through their
physicians to the British Diabetic Twin Study, the Barbara Davis Center for
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Childhood Diabetes and Diabetes Prevention TrialNet (USA) and the BMBF
Pediatric Diabetes Biobank (Germany). T1D-associated autoantibodies were
analysed by radioimmunoassay56,57. We established monozygosity by means of
DNA ﬁngerprinting using an AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Life
Technologies) and consultation of clinical data. T1D status was established by
standard criteria58. T1D patients have been treated from diagnosis with insulin and
take highly puriﬁed human insulin at least twice daily. We excluded twins who
were pregnant and twins with signiﬁcant co-morbidities including severe
macrovascular and microvascular complications of diabetes. Umbilical cord blood
was obtained from 35,000 newborns enroled in the DiPiS Study (Sweden)27
between the years 2000 and 2004. From this cohort, we selected 98 neonates of
whom 50 progressed to T1D and 48 did not. Children were followed for 15 years to
monitor if they develop markers of islet autoimmunity and T1D. The samples
consisted of dried cord blood spots dotted onto cards.
Cell sorting and purity analysis. Peripheral blood mononuclear cells were
prepared from 50ml of heparinized blood using Percoll density gradient
separation. CD4þ T cells, CD19þ B cells and CD14þCD16 monocytes were
isolated using MACS according to the manufacturer’s instruction. First, CD19þ
B cells were separated with CD19 MicroBeads (130-050-301, Miltenyi Biotec).
The negative fraction was then washed and incubated with CD16 MicroBeads
(130-045-701, Miltenyi Biotech). The fraction depleted of CD16þ cells was
selected for CD14þ monocytes using CD14 MicroBeads (130-050-201,
Miltenyi Biotech). Finally, the resulting negative fraction was further incubated
with CD4 MicroBeads (130-045-101, Miltenyi Biotech) to obtain CD4þ T cells.
Based on the number of isolated peripheral blood mononuclear cells, we used 50 ml
of CD19 MicroBeads, 20ml of CD14 MicroBeads, and 20ml of CD4 MicroBeads per
10 million total cells. We assessed the puriﬁed cell populations with FACS. The
following antibodies were used at a dilution of 1:11 per 10 million total cells for
each cell type: 20 ml of FITC-conjugated mouse anti-human CD14 clone MjP9
(345784, BD Biosciences) and 10 ml of CD4 clone M-T466 (130-080-501, Miltenyi
Biotech); 10 ml of phycoerythrin (PE)-conjugated mouse anti-human CD19 clone
LT19 (130-091-247, Miltenyi Biotech) and 20 ml of CD16 clone B73.1/leu11c
(332779, BD Biosciences); 5 ml of PerCP-Cy5.5-conjugated mouse anti-human
CD64 clone 10.1 (561194, BD Biosciences); and 5 ml of PE-Cy7-conjugated mouse
anti-human CD45 clone HI30 (MHCD4512, Invitrogen). Cells were incubated with
antibodies at 4 C for 15min, washed with 2ml of phosphate-buffered saline (PBS)
and ethylenediaminetetraacetic acid (EDTA), and re-suspended in a volume of
500ml for FACS analysis. Across all cell types, the mean cell purity was 90%.
DNA extraction. We extracted genomic DNA from MACS-enriched cell
populations using a QIAamp DNA Blood Mini Kit (QIAGEN) according to
manufacturer’s instructions. DNA was extracted from cord blood using a GenSolve
DNA Recovery Kit (Labtech) according to the manufacturer’s instructions. DNA
concentration was determined using a Qubit dsDNA HS Assay Kit (Invitrogen)
and DNA integrity visually inspected on a 2% agarose gel.
Illumina Inﬁnium HumanMethylation450 assay. Genomic DNA was bisulﬁte-
converted using an EZ-96 DNA Methylation MagPrep Kit (Zymo Research)
according to the manufacturer’s instructions. We applied 500 ng of genomic DNA
to bisulﬁte treatment, and eluted puriﬁed, bisulﬁte-converted DNA in 20 ml of
M-Elution Buffer (Zymo Research). DNA methylation levels were measured on
Inﬁnium HumanMethylation450 BeadChips (Illumina) following the manu-
facturer’s protocol. In brief, 4 ml of bisulﬁte-converted DNA was isothermally
ampliﬁed, enzymatically fragmented and precipitated. Next, precipitated DNA was
resuspended in hybridization buffer and dispensed onto the BeadChips. To limit
batch effects, samples were randomly distributed across slides and arrays. The
hybridization was performed at 48 C for 20 h using a Hybridization Oven
(Illumina). After hybridization, BeadChips were washed and processed through a
single-nucleotide extension followed by immunohistochemistry staining using a
Freedom EVO robot (Tecan). Finally, the BeadChips were imaged using an iScan
Microarray Scanner (Illumina).
Illumina Inﬁnium HumanMethylation450 data preprocessing. The DNA
methylation fraction at a speciﬁc CpG site was calculated as b¼M (MþUþ 100) 1,
for which M and U denote methylated and unmethylated ﬂuorescent signal
intensities, respectively. The b-value statistic ranges from absent (b¼ 0) to
complete DNA methylation (b¼ 1) at a speciﬁc CpG. We normalized the
450K array data using BMIQ (Beta MIxture Quantile dilation), an intra-array
normalization method that adjusts the b-values of type-2 design probes into a
statistical distribution characteristic of type-1 probes59. Next, we ﬁltered (1) probes
with median detection P-value Z0.01 in one or more samples; (2) probes with
bead count of o3 in at least 5% of samples; (3) probes mapping to sex
chromosomes; (4) non-CG probes; (5) probes mapping to ambiguous genomic
locations60; and (6) probes harbouring annotated SNPs within 2 bp of the probed
CG irrespective of allele frequency in the European populations, as reported by
dbSNP v135 (ref. 60). Finally, we adjusted for known batch effects using an
empirical Bayesian framework61, as implemented in the ComBat function of the
R package SVA62. The ﬁnal data matrix consisted of b-values across 406,365 CpG
sites 302 samples, that is, 49, 50 and 52 MZ twin pairs in T cells, B cells and
monocytes, respectively.
Identiﬁcation of DMPs and DVPs. To identify DMPs, we applied a paired
t test and estimated the FDR using the R package q-value63. DVPs were identiﬁed
using iEVORA22, an algorithm based on a regularized version of Bartlett’s
test. The algorithm is freely available as an executable R script from the
Supplementary Information of the publication at http://www.nature.com/ncomms/.
A disadvantage of Bartlett’s test is that single outliers can drive the DVP ranking.
Therefore, iEVORA uses a novel procedure to regularize Bartlett’s test, by selecting
CpGs based on signiﬁcant Bartlett’s test P-values, but ranking these selected
features according to t test P-values22. This heuristic method guarantees (1) that
selected CpGs are signiﬁcant DVPs; and (2) that the ranking favours DVPs that are
either DMPs at genome-wide signiﬁcance or as close to being DMPs as possible.
This regularization step favours DVPs that are driven by more frequent outliers
compared with DVPs driven by single outliers. Bartlett’s test P-values from
iEVORA are corrected for multiple testing using the FDR method implemented in
the R package q-value. To keep the number of false positives as small as possible,
avoiding any impact on the top-ranked features, a stringent FDR of o0.001 was
used. Of note, application of an alternative approach, DiffVar (ref. 64), did not
reveal signiﬁcant DVPs at an FDR of o0.05. DiffVar compares the absolute
deviations from the respective group means using a (moderated) t test, as the
method assumes that the differential variability is driven by numerous outliers
within a disease phenotype. This algorithm offers improved control of the type-1
error rate at the expense of reduced power26. Thus, iEVORA can be seen as a
compromise between DiffVar (which ignores differential variability driven by few
outliers resulting in a low type-1 error rate and low sensitivity) and EVORA19
(which favours differential variability driven by single outliers resulting in much
greater sensitivity albeit at the expense of a higher type-1 error rate).
WGBS-seq data preprocessing and DMR calling. Sample preparation and
preprocessing of WGBS-seq data were conducted using previously established
protocols and pipelines65. Sequencing statistics are provided in Supplementary
Table 1. Counts of unmethylated and methylated cytosine in the context of CpG
sites were extracted from the mapped BAM ﬁles using a publicly available
algorithm (https://bitbucket.org/lowelabqmul/bs-seq-dmr-caller). In brief, the
algorithm uses a windowless approach that progresses along the genome and
determines groups of CpG sites that have the same directional difference between
cases and controls. The method requires each CpG to be located within 1,000 bp of
its neighbouring CpG. To determine the signiﬁcance of the DMR, the w2 statistic is
calculated for the pooled counts across each of the CpGs at the locus and across all
the samples. The sample identities are then permutated and a new statistic is
calculated; this is repeated 1,000 times, and the original statistic is compared with
the permutated statistics to produce a P-value for each CpG. Then, the P-value for
each CpG is combined into a single P-value using Fisher’s method. Finally, the
FDR is estimated for each of the DMRs using the R package q-value63.
Whole-genome genotyping and meQTL mapping. The quantity and integrity
of DNA samples were assessed using a NanoDrop spectrophotometer (Thermo
Scientiﬁc). Samples were normalized to a concentration of 50 ng ml 1 before
ampliﬁcation. Then, DNA was hybridized to Inﬁnium HumanOmni2.5–8 v1.2
BeadChips (Illumina), according to the manufacturer’s instructions. Following
genotyping, raw data were imported into GenomeStudio (Illumina), and genotypes
called using the standard cluster ﬁle provided by the arrays. Quality checks,
including comparisons with called versus reported sex and genotype consistency
between twins, were performed using GenomeStudio. We excluded all SNPs with a
minor allele frequency of o5% and Hardy–Weinberg equilibrium o1 10 6,
leaving 609,587 SNPs for subsequent meQTL analysis. Further, we conﬁrmed
matching DNA methylation and genotype data sets by comparison of genotype
calls across the Inﬁnium platforms. To investigate whether DNA methylation levels
at DVPs are correlated with genotypes, we mapped meQTLs genome-wide
using the software Matrix eQTL66. We applied standard parameters except the
P-value output threshold was set to 1 10 8 and the maximum distance between
interactions of CpGs and SNPs was set to 100,000 bp. We included the following
covariates in the linear-additive model: age, sex, batch and T1D status. The analysis
identiﬁed 13,579 CpG sites for T cells, 11,790 for B cells and 15,531 for monocytes
that correlated with at least one SNP. Then, we determined whether T1D-
associated DVPs are enriched at meQTLs compared with random sets of CpGs
(n¼ 10,000).
Assessment of DVPs in additional data sets. We retrieved DNA methylation
proﬁles of CD14þ monocytes and CD4þ T cells from 12 T1D-discordant MZ
twin pairs generated using 27K arrays15. In addition, we used 450K array DNA
methylation proﬁles of CD14þ and CD4þ cells from 201 and 139 unrelated,
healthy individuals, respectively, obtained from the BLUEPRINT Consortium.
From the DVPs identiﬁed using the 450K array in the discovery stage
(FDRo0.001), we selected all probes that were also present in the external data set.
First, we computed the log-ratio of the variances in T1D twins versus healthy
co-twins. To assess congruence between the discovery and validation sets, we then
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calculated the log-ratio of the variances in each set against each other. Finally,
we counted the number of selected DVPs with signiﬁcant P-values in the external
set and the subset of those that were hypervariable and hypovariable in T1D cases.
This resulted in a 2 2 table, with a subsequent Fisher’s exact test allowing us to
statistically assess whether the selected DVPs validate in the external set.
Functional annotation of T1D-associated DVPs. For the enrichment analyses
with regards to gene elements and epigenomic features, we used the annotation
provided by the 450K array annotation manifest. For the analyses with regards to
chromatin states, we retrieved data generated using the core 15-state ChromHMM
model based on ﬁve chromatin marks (H3K4me3, H3K4me1, H3K36me3,
H3K27me3 and H3K9me3) from http://egg2.wustl.edu/roadmap/web_portal/. We
selected chromatin states maps of primary B cells, T cells and monocytes from
peripheral blood, corresponding to the reference epigenome identiﬁers E032, E034
and E029, respectively. Enrichment was assessed by repeated random sampling
(n¼ 1,000) using all probes that passed quality control. T1D-associated DVPs were
linked to genes using the 450K array annotation manifest24. Then, by applying the
function gometh implemented in the R package missMethyl30, genes were
associated with ontology terms and enrichment of these terms was calculated in
relation to all CpG sites on the 450K array platform that passed quality control.
This method takes account of the differing number of probes per gene present on
the 450K array.
Analysis of CD19þ B-cell-speciﬁc regulatory circuits. We retrieved the CD19þ
B cell regulatory network from http://regulatorycircuits.org. The network consists
of 11,997 nodes (genes) and 1,148,319 edges (interactions between transcription
factors and regulatory elements of target genes). We selected all
T1D-associated DVPs that were genome-wide signiﬁcant (P¼ 1.2 10 7).
‘Gene-activating’ DVPs were deﬁned as CpG sites that were either hypomethylated
in T1D twins compared with their healthy co-twins and annotated as TSS1500,
TSS200, 50-UTR or 1stExon on the 450K array annotation manifest; or hyper-
methylated and annotated as Body or 30-UTR. Accordingly, ‘gene-repressing’
DVPs were deﬁned as CpGs that showed hypermethylation at gene promoters or
hypomethylation at gene bodies. We only considered genes that directly interacted
with other genes of the deﬁned gene set. Network modules were identiﬁed using
Gephi (http://gephi.org) and the Lovain method67. Then, we performed functional
enrichment analyses of these modules using the R packages GOstats68 and
ReactomePA69. We tested for overrepresentation of gene ontology (GO) molecular
function terms using the following parameters: conditional¼TRUE and
FDRo0.25 (Benjamini and Hochberg method70). We performed further functional
enrichment tests of the network modules at an FDR of o0.01 using Cytoscape71
and ClueGO72. For these tests, we speciﬁed the following ontologies: GO Biological
Process, GO Immune System Process, GO Molecular Function, KEGG,
REACTOME and WikiPathways. We applied GO Term Fusion and a minimum
number of three genes or 4% of all genes for the corresponding GO category or
pathway. The kappa score was set to 0.4. All enrichment analyses of network
modules were contrasted to all genes in the whole regulatory network that were
also associated with CpG sites passing quality control on the 450K array platform
(n¼ 10,660).
Data availability. All 450K array and WGBS-seq data sets that support the
ﬁndings of this study have been deposited in the European Genome-phenome
Archive (EGA) with the accession code EGAS00001001598 (https://www.ebi.ac.uk/
ega/studies/EGAS00001001598). We retrieved 450K array data sets of CD14þ
and CD4þ cells from EGA with the accession code EGAS00001001456 (https://
www.ebi.ac.uk/ega/studies/EGAS00001001456), and 27K array data sets of CD14þ
and CD4þ cells from Gene Expression Omnibus (GEO) with the accession code
GSE56606 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56606).
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